Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in CNL and aCML
NCT02092324Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jul 2014
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in chronic neutrophilic leukemia (CNL) and Atypical chronic myeloid leukemia (aCML), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Percentage of First 25 Enrolled Patients With a Hematologic Response to Ruxolitinib (Complete Response (CR), Partial Response (PR)). Started Jul 2014; status: completed.
02
Drugs
03
Conditions
chronic neutrophilic leukemia (CNL)Atypical chronic myeloid leukemia (aCML)
Beyond the preview
Go deeper on NCT02092324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092324.